Peter Fernandes

Peter Fernandes

Chairman at The Pulmonary Vascular Research Institute

Net worth: 1 906 $ as of 30/04/2024

69 year
Health Technology
Consumer Services
Commercial Services

Profile

Peter Fernandes is currently the Co-Chairman at The Pulmonary Vascular Research Institute.
He previously worked as the Vice President-Global Regulatory Affairs at Ikaria, Inc. from 2012 to 2015, Head-Regulatory Affairs & Quality Assurance at OptiNose, Inc. from 2010 to 2012, VP-Regulatory Affairs & Quality Assurance at ALTANA Pharma US, Inc. from 2005 to 2007, and Vice President-US Drug Regulatory Affairs at Novartis Pharmaceuticals AG from 2007 to 2010.
He is also currently the Chief Executive, Financial & Accounting Officer at Bellerophon Therapeutics, Inc. starting from 2015.
Mr. Fernandes received his graduate degree from The Grant Government Medical College in 1982 and his undergraduate degree from Principal K.
M.
Kundnani College of Pharmacy.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
31/10/2023 34,649 ( 0.28% ) 1 906 $ 30/04/2024

Peter Fernandes active positions

CompaniesPositionStart
Chairman -
All active positions of Peter Fernandes

Former positions of Peter Fernandes

CompaniesPositionEnd
BELLEROPHON THERAPEUTICS, INC. Chief Executive Officer 15/11/2023
IKARIA, INC. General Counsel 01/05/2015
OPTINOSE, INC. General Counsel 01/09/2012
Novartis Pharmaceuticals AG Corporate Officer/Principal 01/10/2010
General Counsel 01/10/2007
See the detail of Peter Fernandes's experience

Training of Peter Fernandes

The Grant Government Medical College Graduate Degree
Principal K. M. Kundnani College of Pharmacy Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Fernandes's experience

Connections

38

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
OPTINOSE, INC.

Health Technology

BELLEROPHON THERAPEUTICS, INC.

Health Technology

Private companies4

Health Technology

Health Technology

Commercial Services

Novartis Pharmaceuticals AG

See company connections
  1. Stock Market
  2. Insiders
  3. Peter Fernandes
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW